Bora Biologics Partners with DotBio to Develop Novel Tri-Specific Antibody

• Bora Biologics, a division of Bora Pharmaceuticals, will support DotBio in developing and manufacturing its novel tri-specific antibody, DB007.

• The project will be managed from Bora’s 48,400-square-foot centre-of-excellence in Zhubei, Taiwan.

Bora Biologics, a growing division of contract development and manufacturing organisation (CDMO) Bora Pharmaceuticals, has announced its collaboration with DotBio, a Singaporean biopharmaceutical company. Bora will assist in the development and manufacturing of DotBio’s lead asset, DB007, a tri-specific antibody targeting undisclosed cancer markers.

The partnership will leverage Bora’s 48,400-square-foot facility in Zhubei, Taiwan, which specialises in early-stage biologics development. This centre offers a comprehensive range of services, from lead candidate screening and in vitro assays to purification of complex proteins and multi-specific antibodies.

“Bora Biologics offers a tailored development and manufacturing plan that provides end-to-end support for our client’s development programs,” said Bobby Sheng, Chairman and CEO of Bora Group. “With operations up and running in Zhubei, Bora’s team of experts are ready to deliver high-yield processes together with the sophisticated program management capabilities necessary to successfully develop even the most challenging molecules.”

DotBio’s founder and CEO, Ignacio Asial, Ph.D., highlighted Bora’s expertise and facilities as key factors in the collaboration. “Bora’s early-clinical manufacturing facilities in Taiwan align perfectly with our current IND-development stage, while their large-scale, commercial-stage manufacturing and fill-and-finish facilities in the United States will support our goal to treat patients globally,” said Dr. Asial.